Obesity and Diabetic Kidney Disease

Medical Clinics of North America

Volumn 97, Issue 1, 2013, Pages 59-74

  Maric Bilkan, Christine ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Diabetic nephropathy; Glomerulopathy; Hyperfiltration; Hypertension; Kidney; Obesity; Proteinuria

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; BODY MASS; BODY SIZE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; FOLLOW UP; GLOMERULOPATHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FAILURE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; ULTRAFILTRATION;

ADIPONECTIN; ANIMALS; CARDIOVASCULAR DISEASES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EARLY MEDICAL INTERVENTION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LEPTIN; MEDICATION THERAPY MANAGEMENT; MICE; MODELS, ANIMAL; OBESITY; RISK REDUCTION BEHAVIOR;

EID: 84871725294     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.10.010     Document Type: Review

References (115)

1. Yanovski S.Z., Yanovski J.A. Obesity prevalence in the United States-up, down, or sideways?. N Engl J Med 2011, 364(11):987-989.
2. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303(3):235-241.
3. World Health Organization. Obesity and overweight fact sheet. 2012. Available at: Accessed on October 2nd, 2012. http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
4. Kopelman P. Health risks associated with overweight and obesity. Obes Rev 2007, 8(Suppl 1):13-17.
5. Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep 2007, 7(6):449-453.
6. Hall J.E., Crook E.D., Jones D.W., et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324(3):127-137.
7. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295(13):1549-1555.
8. Neeland I.J., Turer A.T., Ayers C.R., et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012, 308(11):1150-1159.
9. Foster M.C., Hwang S.J., Larson M.G., et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008, 52(1):39-48.
10. Hsu C.Y., McCulloch C.E., Iribarren C., et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006, 144(1):21-28.
11. Ejerblad E., Fored C.M., Lindblad P., et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006, 17(6):1695-1702.
12. Praga M., Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens 2006, 15(5):481-486.
13. Wang Y., Chen X., Song Y., et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008, 73(1):19-33.
14. Ogden C.L., Yanovski S.Z., Carroll M.D., et al. The epidemiology of obesity. Gastroenterology 2007, 132(6):2087-2102.
15. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):2038-2047.
16. Kramer H., Luke A., Bidani A., et al. Obesity and prevalent and incident CKD: the hypertension detection and follow-up program. Am J Kidney Dis 2005, 46(4):587-594.
17. de Zeeuw D., Ramjit D., Zhang Z., et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 2006, 69(9):1675-1682.
18. Remuzzi G., Macia M., Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006, 17(4 Suppl 2):S90-S97.
19. US Renal Data System USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States 2009, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD).
20. Thomson S.C., Vallon V., Blantz R.C. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2004, 286(1):F8-F15.
21. Hostetter T.H. Hyperfiltration and glomerulosclerosis. Semin Nephrol 2003, 23(2):194-199.
22. Caramori M.L., Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003, 12(3):273-282.
23. Leon C.A., Raij L. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy. J Hypertens 2005, 23(11):1931-1937.
24. Ogden C.L., Carroll M.D., Kit B.K., et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012, 307(5):483-490.
25. Flegal K.M., Carroll M.D., Kit B.K., et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307(5):491-497.
26. Danaei G., Finucane M.M., Lin J.K., et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011, 377(9765):568-577.
27. US Renal Data System USRDS 2006 annual data report: atlas of end-stage renal disease in the United States 2006, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD).
28. Kurella M., Lo J.C., Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005, 16(7):2134-2140.
29. Chen J., Muntner P., Hamm L.L., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004, 140(3):167-174.
30. Stengel B., Tarver-Carr M.E., Powe N.R., et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003, 14(4):479-487.
31. Gelber R.P., Kurth T., Kausz A.T., et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005, 46(5):871-880.
32. Munkhaugen J., Lydersen S., Wideroe T.E., et al. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis 2009, 54(4):638-646.
33. Iseki K., Ikemiya Y., Kinjo K., et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004, 65(5):1870-1876.
34. Kramer H.J., Saranathan A., Luke A., et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006, 17(5):1453-1459.
35. Kalantar-Zadeh K., Kopple J.D. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006, 151:57-69.
36. Kalantar-Zadeh K., Streja E., Kovesdy C.P., et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010, 85(11):991-1001.
37. Elsayed E.F., Sarnak M.J., Tighiouart H., et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis 2008, 52(1):29-38.
38. Elsayed E.F., Tighiouart H., Weiner D.E., et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis 2008, 52(1):49-57.
39. Henegar J.R., Bigler S.A., Henegar L.K., et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001, 12(6):1211-1217.
40. Maddox D.A., Alavi F.K., Santella R.N., et al. Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. Kidney Int 2002, 62(1):208-219.
41. Chagnac A., Weinstein T., Herman M., et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003, 14(6):1480-1486.
42. Hall J.E. The kidney, hypertension, and obesity. Hypertension 2003, 41(3 Pt 2):625-633.
43. Griffin K.A., Kramer H., Bidani A.K. Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008, 294(4):F685-F696.
44. Hall J.E., Kuo J.J., da Silva A.A., et al. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens 2003, 12(2):195-200.
45. Esler M., Rumantir M., Wiesner G., et al. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001, 14(11 Pt 2):304S-309S.
46. Blanco S., Bonet J., Lopez D., et al. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl 2005, (93):S10-S14.
47. Chagnac A., Herman M., Zingerman B., et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008, 23(12):3946-3952.
48. Yip J.W., Jones S.L., Wiseman M.J., et al. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. Diabetes 1996, 45(12):1729-1733.
49. Vallon V., Schroth J., Satriano J., et al. Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus. Nephron Physiol 2009, 111(3):p30-p38.
50. Woods L.L., Mizelle H.L., Hall J.E. Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback. Am J Physiol 1987, 252(1 Pt 2):F65-F73.
51. Persson P., Hansell P., Palm F. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf) 2010, 200(1):3-10.
52. Cherney D.Z., Scholey J.W., Miller J.A. Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev 2008, 4(4):280-290.
53. Carmines P.K. The renal vascular response to diabetes. Curr Opin Nephrol Hypertens 2010, 19(1):85-90.
54. do Carmo J.M., Tallam L.S., Roberts J.V., et al. Impact of obesity on renal structure and function in the presence and absence of hypertension: evidence from melanocortin-4 receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol 2009, 297(3):R803-R812.
55. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59(1):260-269.
56. Must A., Spadano J., Coakley E.H., et al. The disease burden associated with overweight and obesity. JAMA 1999, 282(16):1523-1529.
57. Wilson P.W., D'Agostino R.B., Sullivan L., et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002, 162(16):1867-1872.
58. Doll S., Paccaud F., Bovet P., et al. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord 2002, 26(1):48-57.
59. Hall J.E., Jones D.W., Kuo J.J., et al. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 2003, 5(5):386-392.
60. Neter J.E., Stam B.E., Kok F.J., et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42(5):878-884.
61. Garrison R.J., Kannel W.B., Stokes J., et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16(2):235-251.
62. Kannel W.B., Zhang T., Garrison R.J. Is obesity-related hypertension less of a cardiovascular risk? The Framingham Study. Am Heart J 1990, 120(5):1195-1201.
63. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289(1):76-79.
64. Kotchen T.A. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010, 23(11):1170-1178.
65. Hall J.E., Henegar J.R., Dwyer T.M., et al. Is obesity a major cause of chronic kidney disease?. Adv Ren Replace Ther 2004, 11(1):41-54.
66. Van Buren P.N., Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis 2011, 18(1):28-41.
67. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010, 122(8):847-849.
68. Heerspink H.J., de Zeeuw D. The kidney in type 2 diabetes therapy. Rev Diabet Stud 2011, 8(3):392-402.
69. Rayner H.C., Hollingworth L., Higgins R., et al. Systematic kidney disease management in a population with diabetes mellitus: turning the tide of kidney failure. BMJ Qual Saf 2011, 20(10):903-910.
70. Williams M.E. The goal of blood pressure control for prevention of early diabetic microvascular complications. Curr Diab Rep 2011, 11(4):323-329.
71. Grossman E., Messerli F.H. Management of blood pressure in patients with diabetes. Am J Hypertens 2011, 24(8):863-875.
72. Jauregui A., Mintz D.H., Mundel P., et al. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens 2009, 18(6):539-545.
73. de Boer I.H., Sibley S.D., Kestenbaum B., et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007, 18(1):235-243.
74. Eijkelkamp W.B., Zhang Z., Remuzzi G., et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007, 18(5):1540-1546.
75. Klausen K.P., Parving H.H., Scharling H., et al. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol (Oxf) 2009, 71(1):40-45.
76. Savage S., Nagel N.J., Estacio R.O., et al. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis 1995, 25(6):836-844.
77. de Jong P.E., Verhave J.C., Pinto-Sietsma S.J., et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002, 26(Suppl 4):S21-S24.
78. Kohler K.A., McClellan W.M., Ziemer D.C., et al. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. Am J Kidney Dis 2000, 36(5):903-913.
79. Pinto-Sietsma S.J., Navis G., Janssen W.M., et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003, 41(4):733-741.
80. Morales E., Valero M.A., Leon M., et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003, 41(2):319-327.
81. Praga M., Morales E. Obesity-related renal damage: changing diet to avoid progression. Kidney Int 2010, 78(7):633-635.
82. Mohan S., Tan J., Gorantla S., et al. Early improvement in albuminuria in non-diabetic patients after Roux-en-Y bariatric surgery. Obes Surg 2012, 22(3):375-380.
83. Sharma K., Ramachandrarao S., Qiu G., et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008, 118(5):1645-1656.
84. Comper W.D., Russo L.M. The glomerular filter: an imperfect barrier is required for perfect renal function. Curr Opin Nephrol Hypertens 2009, 18(4):336-342.
85. Kasiske B.L., Cleary M.P., O'Donnell M.P., et al. Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 1985, 106(5):598-604.
86. Tran H.A. Obesity-related glomerulopathy. J Clin Endocrinol Metab 2004, 89(12):6358.
87. Ritz E., Koleganova N., Piecha G. Is there an obesity-metabolic syndrome related glomerulopathy?. Curr Opin Nephrol Hypertens 2011, 20(1):44-49.
88. Kasiske B.L., Napier J. Glomerular sclerosis in patients with massive obesity. Am J Nephrol 1985, 5(1):45-50.
89. Coimbra T.M., Janssen U., Grone H.J., et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000, 57(1):167-182.
90. O'Donnell M.P., Kasiske B.L., Cleary M.P., et al. Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med 1985, 106(5):605-610.
91. Kambham N., Markowitz G.S., Valeri A.M., et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001, 59(4):1498-1509.
92. Praga M., Hernandez E., Morales E., et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001, 16(9):1790-1798.
93. Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant 2005, 20(12):2594-2597.
94. King G.L. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008, 79(Suppl 8):1527-1534.
95. Tang J., Yan H., Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol 2012, 2012:608397.
96. Guebre-Egziabher F., Bernhard J., Funahashi T., et al. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005, 20(1):129-134.
97. Saraheimo M., Forsblom C., Thorn L., et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008, 31(6):1165-1169.
98. Ma K., Cabrero A., Saha P.K., et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002, 277(38):34658-34661.
99. Kastarinen H., Kesaniemi Y.A., Ukkola O. Leptin and lipid metabolism in chronic kidney failure. Scand J Clin Lab Invest 2009, 69(3):401-408.
100. Sharma K., Considine R.V., Michael B., et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997, 51(6):1980-1985.
101. Mathew A.V., Okada S., Sharma K. Obesity related kidney disease. Curr Diabetes Rev 2011, 7(1):41-49.
102. Wolf G., Ziyadeh F.N. Leptin and renal fibrosis. Contrib Nephrol 2006, 151:175-183.
103. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005, 69(1):29-35.
104. Gupta J., Mitra N., Kanetsky P.A., et al. Association between albuminuria, kidney function, and inflammatory biomarker profile. Clin J Am Soc Nephrol 2012, 10.2215/CJN.03500412.
105. Ruiz-Ortega M., Ruperez M., Lorenzo O., et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002, (82):S12-S22.
106. Ikezumi Y., Suzuki T., Karasawa T., et al. Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases. Biochem Biophys Res Commun 2008, 376(4):706-711.
107. Patel N.S., Chatterjee P.K., Di Paola R., et al. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther 2005, 312(3):1170-1178.
108. Tomiyama-Hanayama M., Rakugi H., Kohara M., et al. Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice. Am J Physiol Renal Physiol 2009, 297(3):F679-F684.
109. Ahmed S.B., Fisher N.D., Stevanovic R., et al. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005, 46(6):1316-1320.
110. Kennefick T.M., Anderson S. Role of angiotensin II in diabetic nephropathy. Semin Nephrol 1997, 17(5):441-447.
111. Zhuo J.L., Li X.C. Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cells. J Renin Angiotensin Aldosterone Syst 2007, 8(1):23-33.
112. Griffin K.A., Bidani A.K. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006, 1(5):1054-1065.
113. Crowley S.D., Gurley S.B., Coffman T.M. AT(1) receptors and control of blood pressure: the kidney and more. Trends Cardiovasc Med 2007, 17(1):30-34.
114. Ziyadeh F.N. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004, 15(Suppl 1):S55-S57.
115. Jiang G., Li Z., Liu F., et al. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 2005, 115(4):1030-1038.